Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Postmarketing Requirements Will Be "Studies" Unless "Trials" Are Needed, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance lays out the FDAAA-mandated distinction, but also suggests that the agency continues to be much more comfortable with clinical trials than observational studies.

You may also be interested in...



Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards

The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry

Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards

The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry

Sentinel Safety Surveillance Not Ideal For Every Product, Reports Find

Before considering whether to use its nascent Sentinel safety surveillance system, FDA should see whether traditional methods might work just as well, according to two reports commissioned by the agency

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel